Last mentioned: Mar 8, 2026
Enrollment Milestone
Estimated completion of patient enrollment for the global Phase 3 study.
Phase 3 Initiation
Expected launch of the global Phase 3 program for BPL-003 in TRD.
Phase 3 Launch Window
Expected start of the pivotal Phase 3 trial for Treatment-Resistant Depression.
Results Announcement
Company reports 2025 results and confirms Phase 3 timeline.
Earnings & Timeline Release
Company announces 2025 results and sets Q2 2026 for BPL-003 Phase 3 launch.
Fiscal Year End
AtaiBeckley completes 2025 with focused R&D spending on lead assets.
FY 2025 Close
End of the fiscal year reporting period for AtaiBeckley.
Strategic Investment
atai Life Sciences invests $50M in Beckley Psytech to accelerate BPL-003.
AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.
AtaiBeckley has announced its 2025 financial results, highlighted by the upcoming Q2 2026 Phase 3 trial launch for its lead candidate, BPL-003. The intranasal 5-MeO-DMT compound is positioned as a potential blockbuster for treatment-resistant depression with a significantly shorter clinical footprint than existing therapies.